再発頭頸部がん扁平上皮がんの世界市場レポート 2025年

再発頭頸部がん扁平上皮がん市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.0％で43億6,000万米ドルに成長します。予測期間の成長は、生物製剤の需要増加、遠隔医療の利用増加、支持療法への注目の高まり、併存疾患の有病率の増加、医療保険適用の拡大が牽引するとみられます。主な動向としては、ロボット支援手術技術の発展、放射線治療技術の革新、3Dプリンティング・アプリケーションの進歩、二重特異性抗体の開発、画像診断における人工知能の統合などが挙げられます。

個別化医療の拡大が再発頭頸部がん扁平上皮がん市場の成長を牽引すると予想されます。個別化医療とは、遺伝子プロファイル、環境、ライフスタイルなど、個々の患者の特性に基づいて治療やヘルスケアに関する決定をカスタマイズする医療アプローチです。個別化医療の台頭は、ゲノム研究の進歩、診断技術の向上、オーダーメイド治療への需要の高まり、精密医療への投資の増加によって促進され、より効果的で個別化された治療が可能となっています。再発頭頸部がん扁平上皮がんの治療において、個別化医療は、遺伝子プロファイリングと標的治療の使用により、各患者の腫瘍に固有の分子特性に特異的に対処する治療計画を立てることを可能にします。例えば、2024年2月、個別化医療の導入を提唱する米国の組織である個別化医療連合（Personalized Medicine Coalition）は、米国食品医薬品局が希少疾患患者のために16の新しい個別化治療を承認したと報告し、これは2022年の6から増加しました。その結果、個別化医療の成長が再発頭頸部がん扁平上皮がん市場の拡大に寄与しています。

再発頭頸部がん扁平上皮がん市場の主要企業は、治療効果を高め、患者の転帰を改善し、この攻撃的ながんに関連するアンメット・メディカル・ニーズに対応するため、革新的な免疫がん治療薬の開発に注力しています。免疫オンコロジー治療薬は、免疫細胞の活性を高めるか、免疫細胞が腫瘍を標的とするのを妨げる免疫チェックポイントをブロックすることにより、免疫応答を刺激または強化することで、身体の免疫系を利用してがん細胞を検出・攻撃します。例えば、2024年8月、米国の製薬会社Aveta Biomics Inc.は、米国食品医薬品局（FDA）から、頭頸部がんの治療薬としてウコン由来の治験用免疫腫瘍薬APG-157のファスト・トラック指定を受けた。APG-157は、ウコン由来の免疫腫瘍薬で、頭頸部がんの治療薬としてFDA（米国食品医薬品局）より迅速承認されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界再発頭頸部がん扁平上皮がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の再発頭頸部がん扁平上皮がん市場：成長率分析
• 世界の再発頭頸部がん扁平上皮がん市場の実績：規模と成長, 2019-2024
• 世界の再発頭頸部がん扁平上皮がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界再発頭頸部がん扁平上皮がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の再発頭頸部がん扁平上皮がん市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 免疫療法
• 標的薬物療法
• その他の治療の種類
• 世界の再発頭頸部がん扁平上皮がん市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の再発頭頸部がん扁平上皮がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 診断センター
• 調査室
• その他のエンドユーザー
• 世界の再発頭頸部がん扁平上皮がん市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シスプラチン
• カルボプラチン
• 5-フルオロウラシル（5-FU）
• パクリタキセル
• ドセタキセル
• 世界の再発頭頸部がん扁平上皮がん市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペンブロリズマブ
• ニボルマブ
• イピリムマブ
• アテゾリズマブ
• デュルバルマブ
• 世界の再発頭頸部がん扁平上皮がん市場標的薬物療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• セツキシマブ
• アファチニブ
• エルロチニブ
• パニツムマブ
• ラパチニブ
• 世界の再発頭頸部がん扁平上皮がん市場、その他の治療タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線治療
• 手術
• 併用療法
• 緩和ケア

第7章 地域別・国別分析

• 世界の再発頭頸部がん扁平上皮がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の再発頭頸部がん扁平上皮がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 再発頭頸部がん扁平上皮がん市場：競合情勢
• 再発頭頸部がん扁平上皮がん市場：企業プロファイル
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Eisai Co. Ltd.
• Incyte Corporation
• BeiGene Ltd.
• BioNTech SE
• Exelixis Inc.
• CytomX Therapeutics Inc.
• CureVac AG
• Zymeworks Inc.
• MacroGenics Inc.
• Kura Oncology Inc.
• Genexine Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 再発頭頸部がん扁平上皮がん市場2029：新たな機会を提供する国
• 再発頭頸部がん扁平上皮がん市場2029：新たな機会を提供するセグメント
• 再発頭頸部がん扁平上皮がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Recurrent head and neck cancer squamous cell carcinoma refers to the reappearance of squamous cell carcinoma in the head and neck region after initial treatment, originating from the mucosal epithelium. It is associated with a poor prognosis, with median survival rates ranging from 6 to 15 months, highlighting the need for innovative treatment strategies and multimodal management approaches.

The primary treatment options for recurrent head and neck cancer squamous cell carcinoma include chemotherapy, immunotherapy, targeted drug therapy, and others. Chemotherapy involves the use of potent drugs to destroy or slow the growth of cancer cells. Treatment is administered through various routes, including oral and parenteral methods, and is utilized by multiple end users such as hospitals, clinics, diagnostic centers, and research laboratories.

The recurrent head and neck cancer squamous cell carcinoma market research report is one of a series of new reports from The Business Research Company that provides recurrent head and neck cancer squamous cell carcinoma market statistics, including the recurrent head and neck cancer squamous cell carcinoma industry's global market size, regional shares, competitors with a recurrent head and neck cancer squamous cell carcinoma market share, detailed recurrent head and neck cancer squamous cell carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the recurrent head and neck cancer squamous cell carcinoma industry. This recurrent head and neck cancer squamous cell carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The recurrent head and neck cancer squamous cell carcinoma market size has grown strongly in recent years. It will grow from $3.10 billion in 2024 to $3.33 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period was driven by the increasing prevalence of head and neck cancers worldwide, greater awareness of early detection and treatment options, a growing geriatric population, the expanding availability of combination therapies, and a rise in healthcare expenditure.

The recurrent head and neck cancer squamous cell carcinoma market size is expected to see strong growth in the next few years. It will grow to $4.36 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period is expected to be driven by the rising demand for biologics, increased use of telemedicine, a growing focus on supportive care, the increasing prevalence of comorbidities, and expanding health insurance coverage. Key trends include advancements in robotic-assisted surgical techniques, innovations in radiation therapy technologies, progress in 3D printing applications, the development of bispecific antibodies, and the integration of artificial intelligence in diagnostic imaging.

The expansion of personalized medicine is expected to drive the growth of the recurrent head and neck cancer squamous cell carcinoma market. Personalized medicine is a medical approach that customizes treatment and healthcare decisions based on individual patient characteristics, such as genetic profile, environment, and lifestyle. The rise of personalized medicine is fueled by advancements in genomic research, improved diagnostic technologies, increasing demand for tailored treatments, and growing investments in precision healthcare, allowing for more effective and individualized therapies. In the treatment of recurrent head and neck cancer squamous cell carcinoma, personalized medicine enables the use of genetic profiling and targeted therapies to develop treatment plans that specifically address the unique molecular characteristics of each patient's tumor. For example, in February 2024, the Personalized Medicine Coalition, a US-based organization advocating for the adoption of personalized medicine, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the growth of personalized medicine is contributing to the expansion of the recurrent head and neck cancer squamous cell carcinoma market.

Leading companies in the recurrent head and neck cancer squamous cell carcinoma market are focusing on developing innovative immuno-oncology drugs to enhance treatment efficacy, improve patient outcomes, and address the unmet medical needs associated with this aggressive form of cancer. Immuno-oncology drugs harness the body's immune system to detect and attack cancer cells by stimulating or enhancing immune responses, either by boosting immune cell activity or by blocking immune checkpoints that prevent immune cells from targeting tumors. For instance, in August 2024, Aveta Biomics Inc., a US-based pharmaceutical company, received fast-track designation from the U.S. Food and Drug Administration (FDA) for APG-157, an investigational immuno-oncology agent derived from turmeric for the treatment of head and neck cancer. Its dual mechanism selectively targets cancer cells while reshaping the immune environment, potentially offering a less invasive alternative to surgery and intensive therapies.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition strengthens AstraZeneca's oncology portfolio by incorporating advanced radiopharmaceuticals such as FPI-2265, enhancing research and development as well as manufacturing capabilities. The move accelerates the transition to targeted cancer therapies while expanding AstraZeneca's presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based company specializing in next-generation radiopharmaceuticals designed as precision medicines for oncology.

Major players in the recurrent head and neck cancer squamous cell carcinoma market are Roche Holding AG, Merck KGaA, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Incyte Corporation, BeiGene Ltd., BioNTech SE, Exelixis Inc., CytomX Therapeutics Inc., CureVac AG, Zymeworks Inc., MacroGenics Inc., Kura Oncology Inc., Genexine Inc.

North America was the largest region in the recurrent head and neck cancer squamous cell carcinoma market in 2024. The regions covered in recurrent head and neck cancer squamous cell carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the recurrent head and neck cancer squamous cell carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The recurrent head and neck cancer squamous cell carcinoma market includes revenues earned by entities by providing services such as diagnostic services, surgical services, radiation therapy, and multidisciplinary care and related products such as linear accelerators, positron emission tomography (PET) scanners, and magnetic resonance imaging (MRI) machines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on recurrent head and neck cancer squamous cell carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for recurrent head and neck cancer squamous cell carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The recurrent head and neck cancer squamous cell carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Immunotherapy; Targeted Drug Therapy; Other Treatment Types
• 2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 3) By End User: Hospitals; Clinics; Diagnostic Centers; Research Laboratories; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Cisplatin; Carboplatin; 5-Fluorouracil (5-FU); Paclitaxel; Docetaxel
• 2) By Immunotherapy: Pembrolizumab; Nivolumab; Ipilimumab; Atezolizumab; Durvalumab
• 3) By Targeted Drug Therapy: Cetuximab; Afatinib; Erlotinib; Panitumumab; Lapatinib
• 4) By Other Treatment Types: Radiation Therapy; Surgery; Combination Therapies; Palliative Care
• Companies Mentioned:Roche Holding AG; Merck KGaA; AbbVie Inc.; Bristol-Myers Squibb Company; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Characteristics

3. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Trends And Strategies

4. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Growth Rate Analysis
• 5.4. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Total Addressable Market (TAM)

6. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Segmentation

• 6.1. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Drug Therapy
• Other Treatment Types
• 6.2. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.3. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Diagnostic Centers
• Research Laboratories
• Other End-Users
• 6.4. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cisplatin
• Carboplatin
• 5-Fluorouracil (5-FU)
• Paclitaxel
• Docetaxel
• 6.5. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pembrolizumab
• Nivolumab
• Ipilimumab
• Atezolizumab
• Durvalumab
• 6.6. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Sub-Segmentation Of Targeted Drug Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cetuximab
• Afatinib
• Erlotinib
• Panitumumab
• Lapatinib
• 6.7. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiation Therapy
• Surgery
• Combination Therapies
• Palliative Care

7. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Regional And Country Analysis

• 7.1. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 8.1. Asia-Pacific Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 9.1. China Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 9.2. China Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 10.1. India Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 11.1. Japan Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 11.2. Japan Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 12.1. Australia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 13.1. Indonesia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 14.1. South Korea Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 14.2. South Korea Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 15.1. Western Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 15.2. Western Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 16.1. UK Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 17.1. Germany Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 18.1. France Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 19.1. Italy Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 20.1. Spain Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 21.1. Eastern Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 21.2. Eastern Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 22.1. Russia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 23.1. North America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 23.2. North America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 24.1. USA Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 24.2. USA Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 25.1. Canada Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 25.2. Canada Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 26.1. South America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 26.2. South America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 27.1. Brazil Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 28.1. Middle East Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 28.2. Middle East Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

• 29.1. Africa Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Overview
• 29.2. Africa Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Competitive Landscape And Company Profiles

• 30.1. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Competitive Landscape
• 30.2. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Company Profiles
  • 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Gilead Sciences Inc.
• 31.3. Amgen Inc.
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. Eisai Co. Ltd.
• 31.6. Incyte Corporation
• 31.7. BeiGene Ltd.
• 31.8. BioNTech SE
• 31.9. Exelixis Inc.
• 31.10. CytomX Therapeutics Inc.
• 31.11. CureVac AG
• 31.12. Zymeworks Inc.
• 31.13. MacroGenics Inc.
• 31.14. Kura Oncology Inc.
• 31.15. Genexine Inc.

32. Global Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

34. Recent Developments In The Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

35. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market High Potential Countries, Segments and Strategies

• 35.1 Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer